Overview
Cytokeratin 7 (CK7) is a type II cytokeratin encoded by the KRT7 gene. It is an intermediate filament protein expressed in specific epithelial tissues. CK7 is characteristically expressed in the epithelial lining of the lung, breast, ovary, and endometrium, as well as in transitional epithelium. In general, CK7 is found in simple, pseudostratified, and ductal epithelium, along with mesothelium and urothelium.
Importantly, CK7 is not expressed in the glandular epithelium of the colon and prostate, making it a valuable immunohistochemical marker for tumor differentiation. CK7 plays a crucial diagnostic role in identifying the tissue of origin in epithelial malignancies, particularly when used in combination with CK20. CK7
Symptoms
CK7 itself does not cause symptoms; instead, its clinical relevance lies in the evaluation of epithelial tumors. Symptoms in patients undergoing CK7 testing depend on the underlying malignancy and the organ system involved. These may include manifestations related to tumors of the lung, breast, gynecological organs, salivary glands, gastrointestinal tract, or urinary tract. CK7 expression assists pathologists in correlating histopathological findings with clinical presentation.
Causes
CK7 expression reflects the epithelial origin and differentiation pattern of tissues and tumors. It is commonly expressed in epithelial tumors such as breast carcinoma, lung adenocarcinoma, endometrial carcinoma, ovarian carcinoma, cervical carcinoma, urothelial carcinoma, salivary gland tumors, Paget’s disease, papillary renal cell carcinoma, and upper gastrointestinal tract tumors.
Conversely, CK7 is typically negative in colorectal carcinoma, hepatocellular carcinoma, prostatic adenocarcinoma, follicular carcinoma of the thyroid, adrenocortical tumors, and squamous cell carcinoma. Certain tumors, such as papillary thyroid carcinoma, may show weak CK7 staining. These expression patterns aid in narrowing differential diagnoses, especially in metastatic tumors of unknown primary origin.
Risk Factors
CK7 expression patterns are closely associated with tumor grade and prognosis in specific cancers. In ampullary adenocarcinoma, advanced tumor stage is a significant prognostic factor, and positive CK7 expression combined with negative CK20 expression is independently associated with overall survival.
CK7-positive tumors are more frequently high-grade, whereas CK7-negative tumors tend to be low-grade. Survival analysis indicates that patients with CK7-positive tumors have an approximate 5-year survival rate of 30%, compared to around 65% in CK7-negative groups. These findings highlight the prognostic importance of CK7 expression in selected malignancies.
Prevention
There is no direct prevention related to CK7 expression, as it is a biological marker rather than a disease entity. However, accurate diagnosis and prognosis depend on proper immunohistochemical evaluation. CK7 testing is performed on formalin-fixed, paraffin-embedded tissue using immunohistochemistry.
CK7 typically demonstrates diffuse cytoplasmic staining, though staining intensity and distribution vary according to tissue type and cellular characteristics. Internal positive controls are essential for quality assurance and include bronchial or glandular epithelial cells in lung tissue, ductal epithelial cells in breast tissue, and tubular epithelial cells in kidney tissue.
The combined use of CK7 and CK20 significantly enhances diagnostic accuracy by helping differentiate between primary tumors, metastatic lesions, and tumor extensions. This combined immunoprofile plays a major role in the classification and management of various epithelial malignancies and supports appropriate clinical decision-making.
